PRA Health Sciences Inc (PRAH) VP Sells $6,048,090.00 in Stock

PRA Health Sciences Inc (NASDAQ:PRAH) VP Linda Baddour sold 67,000 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $90.27, for a total transaction of $6,048,090.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.

PRA Health Sciences Inc (NASDAQ PRAH) opened at $93.50 on Friday. PRA Health Sciences Inc has a 1-year low of $54.08 and a 1-year high of $94.28. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.01 and a quick ratio of 1.01. The company has a market cap of $5,886.41, a P/E ratio of 52.23, a P/E/G ratio of 1.29 and a beta of 0.41.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The firm had revenue of $494.55 million for the quarter, compared to analyst estimates of $477.89 million. During the same quarter last year, the firm posted $0.64 earnings per share. PRA Health Sciences’s revenue for the quarter was up 23.7% compared to the same quarter last year. equities analysts expect that PRA Health Sciences Inc will post 3.2 EPS for the current fiscal year.

Several brokerages have recently weighed in on PRAH. Zacks Investment Research lowered shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Thursday. BidaskClub upgraded shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 27th. Mitsubishi UFJ Financial Group assumed coverage on shares of PRA Health Sciences in a report on Friday, December 15th. They issued an “overweight” rating and a $102.00 price target on the stock. Barclays assumed coverage on shares of PRA Health Sciences in a report on Monday, December 11th. They issued an “overweight” rating and a $94.00 price target on the stock. Finally, Mizuho set a $87.00 price target on shares of PRA Health Sciences and gave the company a “buy” rating in a report on Friday, December 1st. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $91.85.

Institutional investors and hedge funds have recently bought and sold shares of the company. Magnetar Financial LLC purchased a new stake in shares of PRA Health Sciences during the third quarter valued at approximately $5,010,000. Amalgamated Bank purchased a new stake in shares of PRA Health Sciences during the second quarter valued at approximately $370,000. Fred Alger Management Inc. raised its stake in shares of PRA Health Sciences by 9.4% during the second quarter. Fred Alger Management Inc. now owns 92,853 shares of the medical research company’s stock valued at $6,965,000 after purchasing an additional 7,990 shares during the period. Sei Investments Co. raised its stake in shares of PRA Health Sciences by 8.5% during the third quarter. Sei Investments Co. now owns 15,899 shares of the medical research company’s stock valued at $1,212,000 after purchasing an additional 1,245 shares during the period. Finally, Alyeska Investment Group L.P. raised its stake in shares of PRA Health Sciences by 12.0% during the third quarter. Alyeska Investment Group L.P. now owns 463,941 shares of the medical research company’s stock valued at $35,338,000 after purchasing an additional 49,693 shares during the period. Institutional investors own 98.23% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “PRA Health Sciences Inc (PRAH) VP Sells $6,048,090.00 in Stock” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3148418/pra-health-sciences-inc-prah-vp-sells-6048090-00-in-stock.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Insider Buying and Selling by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.